BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Press Releases

  Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

  April 27, 2026

   · 

  11 min read
• Press Releases

  HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors

  April 27, 2026

   · 

  4 min read
• Press Releases

  NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer

  April 27, 2026

   · 

  6 min read
• Press Releases

  CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients

  April 27, 2026

   · 

  7 min read
• Press Releases

  BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET

  April 27, 2026

   · 

  1 min read
• Press Releases

  ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026

  April 27, 2026

   · 

  4 min read
• Press Releases

  NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026

  April 27, 2026

   · 

  6 min read
• Press Releases

  Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients

  April 27, 2026

   · 

  4 min read
• 

  Manufacturing

  UCSF, Par Health hit with FDA warning letters for environmental monitoring issues

  FDA inspectors warned UCSF radiopharmaceutical facility that losing environmental control could pose a serious hazard to patients.

  April 27, 2026

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  Gene editing

  Intellia heads to FDA after notching first late-stage win for in vivo gene editor

  With Phase 3 data in hand, Intellia Therapeutics is seeking approval for its in vivo CRISPR gene editing therapy for hereditary angioedema.

  April 27, 2026

   · 

  3 min read

   · 

  Tristan Manalac